Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 819
Publisher
MDPI AG
Online
2020-04-01
DOI
10.3390/cancers12040819
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer
- (2019) Carol Forbes et al. Cancer Management and Research
- Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology
- (2019) Panagiotis Ntellas et al. Oncotarget
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Recent therapeutic trends and promising targets in triple negative breast cancer
- (2019) Soo-Yeon Hwang et al. PHARMACOLOGY & THERAPEUTICS
- MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer
- (2019) Yueh-Shan Weng et al. Molecular Cancer
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
- (2019) Richard Gray et al. LANCET
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- 4ORelationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
- (2019) S Loi et al. ANNALS OF ONCOLOGY
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
- (2019) Ulrike Nitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.
- (2019) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.
- (2019) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).
- (2019) Peter A. Fasching et al. JOURNAL OF CLINICAL ONCOLOGY
- NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto
- (2019) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- Homologous recombination deficiency in triple negative breast cancer
- (2019) Carmen Belli et al. BREAST
- A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements
- (2019) Darrell L. Ellsworth et al. Journal of Oncology
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- (2019) P Schmid et al. ANNALS OF ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis
- (2019) Yan Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
- (2019) Ana Lluch et al. JOURNAL OF CLINICAL ONCOLOGY
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
- (2018) F Poggio et al. ANNALS OF ONCOLOGY
- Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer
- (2018) E Obeid et al. CANCER RESEARCH
- Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
- (2018) L. Gerratana et al. CANCER TREATMENT REVIEWS
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
- (2018) Bernard Asselain et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
- (2018) Peter Savas et al. NATURE MEDICINE
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial
- (2018) Luca Gianni et al. JAMA Oncology
- Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types
- (2018) L Paré et al. ANNALS OF ONCOLOGY
- Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.
- (2018) Romualdo Barroso-Sousa et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)
- (2018) Kathy D. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs
- (2018) Anna Diana et al. Current Oncology Reports
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
- (2018) Alexandra Thomas et al. OncoImmunology
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
- (2017) Joanne L. Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
- (2017) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
- (2017) François Bertucci et al. Current Oncology Reports
- Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
- (2017) L. J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- (2016) R. Bell et al. ANNALS OF ONCOLOGY
- Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
- (2016) Volker Möbus Breast Care
- Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature
- (2016) Mattea Reinisch et al. Breast Care
- Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
- (2016) G von Minckwitz et al. CANCER RESEARCH
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015
- (2016) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
- (2016) Yan Mao et al. PLoS One
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials
- (2015) Fausto Petrelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
- (2015) J.M. Nabholtz et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
- (2015) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
- (2015) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Chemokines in tumor progression and metastasis
- (2015) Purvaba J. Sarvaiya et al. Oncotarget
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†
- (2014) A. M. Gonzalez-Angulo et al. ANNALS OF ONCOLOGY
- Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)†
- (2014) G. von Minckwitz et al. ANNALS OF ONCOLOGY
- Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
- (2014) T. Byrski et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
- (2011) Rachel Sharpe et al. CLINICAL CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
- (2009) Miguel Martín et al. BREAST CANCER RESEARCH AND TREATMENT
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now